Treprostinil treatment decreases circulating platelet microvesicles and their procoagulant activity in pediatric pulmonary hypertension.
Nour C BachaMarilyne LevyCoralie L GuerinBernard Le BonniecAnnie HarrocheIsabelle SzezepanskiJean M RenardPascale GaussemDominique Israel-BietChantal M BoulangerDavid M SmadjaPublished in: Pediatric pulmonology (2018)
Our results suggest that treprostinil, besides vasodilation, might exert its beneficial effect through an inhibition of platelet activation, resulting in a decreased number and procoagulant activity of circulating MVs.